AR and prostate cancer: Recently, hormonal therapy using abiraterone acetate, a second‐generation androgen receptor axis‐targeted agent, was reported to improve overall survival and progression‐free survival in men with LATITUDE‐high‐risk metastatic castration‐sensitive prostate cancer.